Abstract
Drug-induced movement disorders (DIMD) are characterized by abnormal involuntary movements associated to drugs. DIMD frequency is not known and varies widely among publications. They have been identified in the second half of the twentieth century and been growing ever since. Initially they were related to dopamine receptor-blocking agents and LDOPA use, causing parkinsonism and chorea. Other types of movement disorders were also described, namely akathisia, dystonia, myoclonus, neuroleptic malignant syndrome (NMS), tics, and tremor. Since several DIMD only occur after long-term use, its relation to drugs may not always be evident and delay diagnosis. Like other adverse drug reactions (ADRs), most DIMD occur due to an exaggerated pharmacological response and as such are predictable and sometimes preventable. Early identification and treatment may significantly decrease the burden of DIMD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
Meyboom RHB, Royer RJ. Causality classification at pharmacovigilance centres in the european community. Pharmacoepidemiol Drug Saf. 1992;1:87–97.
Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45(1):71–6.
Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry. 1976;39(9):866–9.
WHO. Technical Report No 498. International drug monitoring: the role of national centres. Geneva: WHO; 1972.
European Medicines Agency/Heads of Medicines Agencies. Guideline on good pharmacovigilance practices. Annex I – Definitions. EMA/876333/2011 Rev. 1*. London, December 2012.
Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, Hunter JAA, editors. Davidson’s principles and practice of medicine. 19th ed. Edinburgh: Elsevier Science; 2002. p. 147–63.
Wojcieszek J. Drug-induced movement disorders. In: Biller J, editor. Iatrogenic neurology. Oxford: Butterworth-Heinemann; 1998. p. 215–31.
Jain KK. Drug-induced neurological disorders. 3rd ed. Seattle: Hogrefe Publishing; 2012.
Yassa R, Nastase C, Dupont D, et al. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry. 1992;149:1206–11.
Wu RM, Chiu HC, Wang M, Chen RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm. 1993;5(2):127–33.
Rosa MM. Reacções adversas neuropsiquiátricas. In: Pinheiro L, Marques da Silva P, Carmona R, Maria VA, editors. Farmacovigilância em Portugal. Lisbon: INFARMED – Ministério da Saúde; 2003. p. 303–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Wien
About this chapter
Cite this chapter
Rosa, MM., Anes, AM. (2017). Drug-Induced Movement Disorders. In: Falup-Pecurariu, C., Ferreira, J., Martinez-Martin, P., Chaudhuri, K. (eds) Movement Disorders Curricula. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1628-9_40
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1628-9_40
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1627-2
Online ISBN: 978-3-7091-1628-9
eBook Packages: MedicineMedicine (R0)